Trial · NCT04856176
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
NCT04856176, Phase 2, Terminated, Tufts Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy. Trials, record NCT04856176. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04856176
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
- NCT number
- NCT04856176
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Tufts Medical Center
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed, Paclitaxel, Carboplatin
- First posted
- 2021-04-23
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | 24 Months | Progression is measured according to RECIST 1.1 criteria. |
| Primary | Overall Survival (OS) | 24 months | Patient survival status throughout their participation in the study |
| Secondary | To evaluate changes in monocytes at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
| Secondary | To evaluate changes in myeloid derived suppressor cells at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
| Secondary | To evaluate changes in CD4 T at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
| Secondary | To evaluate changes in CD8 T at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
| Secondary | To evaluate changes in PD-1+ CD4 at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
| Secondary | To evaluate changes in PD-1+ CD8 at different time points during study treatment | 24 Months | Time points include study weeks 0, 12, 14 and 15 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04856176
GET https://conductscience.org/api/trials/v1/NCT04856176/registered